(Q43238251)

17 November 2017

title

Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. (English)

1 reference

17 November 2017

1 reference

Robert Y Lin

1

1 reference

17 November 2017

Gerson Rodriguez-Baez

series ordinal

2

1 reference

17 November 2017

Geeta A Bhargave

series ordinal

3

1 reference

17 November 2017

language of work or name

1 reference

1 November 2009

1 reference

Annals of Allergy, Asthma & Immunology

17 November 2017

published in

1 reference

17 November 2017

volume

103

1 reference

17 November 2017

issue

5

1 reference

17 November 2017

page(s)

442-445

1 reference

Asthma 2008: targeting immunoglobulin E to achieve disease control

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Delayed allergic reactions to omalizumab: are patients reporting all cases?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

The medical dictionary for regulatory activities (MedDRA).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Fatalities following allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960366-3

7 January 2021

10.1016/S1081-1206(10)60366-3

Identifiers

DOI

1 reference

17 November 2017

1 reference